Why Bio-Path Stock Is Soaring
Why Bio-Path Stock Is Soaring
Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are trading higher Thursday after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients.
Bio-Path Holdings, Inc.（納斯達克股票代碼：BPTH）週四股價走高，此前該公司宣佈完成了評估 BP1002 治療難治性/復發急性髓系白血病患者的能力的 BP1002 1/1b期臨床試驗中的第二劑疫苗。
The Details:
細節：
BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Bio-Path said BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.
BP1002 靶向蛋白 Bcl-2，該蛋白負責推動多達 60% 的癌症的細胞存活。Bio-Path 表示，BP1002 可能會克服和預防一些影響 venetoclax 治療的耐藥機制。
"We are delighted to safely progress through the second, higher dose cohort to reach an important study milestone for the United States Food and Drug Administration (FDA) to review patient study data," said Peter Nielsen, CEO of Bio-Path Holdings.
Bio-Path Holdings首席執行官彼得·尼爾森表示：“我們很高興能夠安全地完成第二個更高劑量的隊列，達到美國食品藥品監督管理局（FDA）審查患者研究數據的重要研究里程碑。”
"Enrollment rates have been good, and we look forward to advancing this study in even higher doses with the hope that we can sooner reach the combination therapy segment of our Phase 1/1b study with increased levels of BP1002 for the treatment of these vulnerable patients with few, if any, treatment options," Nielsen added.
尼爾森補充說：“入學率一直不錯，我們期待以更高的劑量推進這項研究，希望我們能夠更快地進入1/1b期研究的聯合療法部分，提高用於治療這些幾乎沒有治療選擇的脆弱患者的 BP1002 水平。”
Bio-Path shares are moving on heavy trading volume Thursday and have been halted for volatility. According to data from Benzinga Pro, more than 40 million shares have already been traded in the session, compared to the stock's 100-day average of less than 39,000 shares.
週四，Bio-Path的股票交易量居高不下，並因波動而暫停。根據Benzinga Pro的數據，該交易日已經交易了超過4000萬股股票，而該股的100天平均交易量不到39,000股。
Related News: What's Going On With Arm Holdings Stock?
相關新聞： Arm Holdings 的股票怎麼了？
How To Buy BPTH Stock:
如何購買 BPTH 股票：
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
除了前往經紀平台購買股票的股票（或部分股票）外，您還可以通過購買本身持有股票的交易所交易基金（ETF）來獲得股票，或者將自己分配到401（k）中尋求收購共同基金或其他工具股票的策略。
For example, in Bio-Path's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
例如，就Bio-Path而言，它屬於醫療保健領域。ETF可能會持有許多有助於追蹤該行業的流動性和大型公司的股票，從而使投資者能夠了解該細分市場的趨勢。
BPTH Price Action: According to Benzinga Pro, Bio-Path shares are up 67% at $5.41 at the time of publication Thursday.
BPTH價格走勢：根據Benzinga Pro的數據，在週四發佈時，Bio-Path股價上漲了67％，至5.41美元。
Image: Phoenix Locklear from Pixabay
圖片：來自 Pixabay 的菲尼克斯·洛克利爾
譯文內容由第三人軟體翻譯。